FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2031337495> ?p ?o ?g. }

• W2031337495 endingPage "568" @default.
• W2031337495 startingPage "568" @default.
• W2031337495 abstract "Back to table of contents Previous article Next article LetterFull AccessPlacebos in ResearchRajnish Mago, M.D., Richard Petty, M.D., and Paul Root Wolpe, Ph.D.Rajnish MagoSearch for more papers by this author, M.D., Richard PettySearch for more papers by this author, M.D., and Paul Root WolpeSearch for more papers by this author, Ph.D.Published Online:1 Apr 1999https://doi.org/10.1176/ps.50.4.568AboutSectionsView EPUB ToolsAdd to favoritesDownload CitationsTrack Citations ShareShare onFacebookTwitterLinked InEmail To the Editor: In a letter to the editor in the May 1998 issue, McCarthy (1) posed important and potentially disturbing questions about the ability of patients with schizophrenia to fully understand the implications of receiving a placebo in a clinical trial and to provide genuine informed consent.We fully agree with McCarthy that all necessary measures should be taken to assess and facilitate patients' understanding of the research process and to safeguard their rights. Investigators and other parties, such as institutional review boards, must be vigilant in this regard. Clearly, the good of society—in particular the interests of other patients with the same disorder—cannot be used to justify encroaching on the principles of beneficence and autonomy as they apply to the individual patient.However, in considering the use of placebos in research, several other issues need to be examined, which we address briefly below.Are there viable alternatives to placebo controls for research? Alternatives to placebo controls include active controls, who receive the standard drug for the condition, and historical controls, which are based on data from previous placebo-controlled studies with similar patients. Several writers have argued that placebo controls are essential to clinical trials in certain circumstances and that alternative control groups are inadequate. Given the need for placebo controls to permit meaningful conclusions to be drawn from clinical studies, it may be argued that not using placebo controls would be unethical because patients receiving the experimental drug would be exposed to potential risks in a study of questionable scientific benefit.What is the potential harm to patients receiving placebo? Conventional antipsychotics are not uniformly effective in schizophrenia, in particular against negative symptoms. Between 30 and 50 percent of patients are exposed to the risk of troublesome adverse effects for minimal or no benefit (2). Also, contrary to popular belief, as many as 55 percent of patients who receive placebo in the acute phase do not worsen, and up to 25 percent are much improved (2,3).In addition, some studies have found that patients who relapse while on placebo do not suffer any long-term consequences. For example, Curson and associates (4) followed patients who had participated in a short-term trial of relapse prevention. They found that although in the original trial 66 percent of patients on placebo had relapsed compared with 8 percent of those on the active drug, there were no differences between the two groups in the number of relapses after the end of the trial or in any clinical or social variable over a seven-year follow-up period.How well informed is the informed consent of patients with schizophrenia who participate in clinical trials? Carpenter and associates (3) have cited recent research suggesting that approximately 75 percent of patients with a diagnosis of schizophrenia incorporate information and make decisions much like comparison groups do when dealing with consent issues.What can be done to protect the individual patient? Explicit guidelines, such as those adopted by Loma Linda University (5) or proposed by Carpenter and associates (3) may aid in protecting psychiatric patients, particularly those with a psychotic disorder, who are enrolled in placebo-controlled trials. Although researchers must continue to be very concerned and vigilant about protecting the rights of subjects participating in research, the use of placebos in research has unique scientific benefits. With proper care, it need not be incompatible with concerns for the safety of the subjects.Dr. Mago is associated with the department of psychiatry at the University of Pennsylvania in Philadelphia. Dr. Petty is clinical director of the neuropsychiatry program and Dr. Wolpe is associated with the Center for Bioethics at the University of Pennsylvania.References1. McCarthy J: Placebo in research on schizophrenia. Psychiatric Services 49:699, 1998Link, Google Scholar2. Addington D: The use of placebos in clinical trials for acute schizophrenia. Canadian Journal of Psychiatry 40:171-176, 1995Crossref, Medline, Google Scholar3. Carpenter WT Jr, Schooler NR, Kane JM: The rationale and ethics of medication-free research in schizophrenia. Archives of General Psychiatry 54:401-407, 1997Crossref, Medline, Google Scholar4. Curson DA, Hirsch SR, Platt SD, et al: Does short-term placebo treatment of chronic schizophrenia produce long-term harm? British Medical Journal, clinical research edition 293:726-728, 1986Google Scholar5. Orr RD: Guidelines for the use of placebo controls in clinical trials of psychopharmacologic agents. Psychiatric Services 47:1262-1264, 1996Link, Google Scholar FiguresReferencesCited byDetailsCited byNone Volume 50Issue 4 April 1999Pages 568-568 Metrics History Published online 1 April 1999 Published in print 1 April 1999" @default.
• W2031337495 created "2016-06-24" @default.
• W2031337495 creator A5020605255 @default.
• W2031337495 creator A5023907204 @default.
• W2031337495 creator A5066631526 @default.
• W2031337495 date "1999-04-01" @default.
• W2031337495 modified "2023-09-25" @default.
• W2031337495 title "Placebos in Research" @default.
• W2031337495 doi "https://doi.org/10.1176/ps.50.4.568" @default.
• W2031337495 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10211750" @default.
• W2031337495 hasPublicationYear "1999" @default.
• W2031337495 type Work @default.
• W2031337495 sameAs 2031337495 @default.
• W2031337495 citedByCount "0" @default.
• W2031337495 crossrefType "journal-article" @default.
• W2031337495 hasAuthorship W2031337495A5020605255 @default.
• W2031337495 hasAuthorship W2031337495A5023907204 @default.
• W2031337495 hasAuthorship W2031337495A5066631526 @default.
• W2031337495 hasConcept C117438556 @default.
• W2031337495 hasConcept C118552586 @default.
• W2031337495 hasConcept C138885662 @default.
• W2031337495 hasConcept C142724271 @default.
• W2031337495 hasConcept C15744967 @default.
• W2031337495 hasConcept C171078966 @default.
• W2031337495 hasConcept C17744445 @default.
• W2031337495 hasConcept C199539241 @default.
• W2031337495 hasConcept C204787440 @default.
• W2031337495 hasConcept C27081682 @default.
• W2031337495 hasConcept C41895202 @default.
• W2031337495 hasConcept C542102704 @default.
• W2031337495 hasConcept C65414064 @default.
• W2031337495 hasConcept C71924100 @default.
• W2031337495 hasConceptScore W2031337495C117438556 @default.
• W2031337495 hasConceptScore W2031337495C118552586 @default.
• W2031337495 hasConceptScore W2031337495C138885662 @default.
• W2031337495 hasConceptScore W2031337495C142724271 @default.
• W2031337495 hasConceptScore W2031337495C15744967 @default.
• W2031337495 hasConceptScore W2031337495C171078966 @default.
• W2031337495 hasConceptScore W2031337495C17744445 @default.
• W2031337495 hasConceptScore W2031337495C199539241 @default.
• W2031337495 hasConceptScore W2031337495C204787440 @default.
• W2031337495 hasConceptScore W2031337495C27081682 @default.
• W2031337495 hasConceptScore W2031337495C41895202 @default.
• W2031337495 hasConceptScore W2031337495C542102704 @default.
• W2031337495 hasConceptScore W2031337495C65414064 @default.
• W2031337495 hasConceptScore W2031337495C71924100 @default.
• W2031337495 hasIssue "4" @default.
• W2031337495 hasLocation W20313374951 @default.
• W2031337495 hasLocation W20313374952 @default.
• W2031337495 hasOpenAccess W2031337495 @default.
• W2031337495 hasPrimaryLocation W20313374951 @default.
• W2031337495 hasRelatedWork W1967980472 @default.
• W2031337495 hasRelatedWork W2062198426 @default.
• W2031337495 hasRelatedWork W2106054528 @default.
• W2031337495 hasRelatedWork W2568257248 @default.
• W2031337495 hasRelatedWork W2591937858 @default.
• W2031337495 hasRelatedWork W2748952813 @default.
• W2031337495 hasRelatedWork W2899084033 @default.
• W2031337495 hasRelatedWork W2954256433 @default.
• W2031337495 hasRelatedWork W2954684344 @default.
• W2031337495 hasRelatedWork W2977219032 @default.
• W2031337495 hasVolume "50" @default.
• W2031337495 isParatext "false" @default.
• W2031337495 isRetracted "false" @default.
• W2031337495 magId "2031337495" @default.
• W2031337495 workType "article" @default.